TY  - JOUR
AU  - Franco-Moreno, Anabel
AU  - Acedo-Gutiérrez, María Soledad
AU  - Martín, Nicolás Labrador-San
AU  - Hernández-Blanco, Clara
AU  - Rodríguez-Olleros, Celia
AU  - Ibáñez-Estéllez, Fátima
AU  - Suárez-Simón, Ana
AU  - Balado-Rico, Mateo
AU  - Romero-Paternina, Ana Rocío
AU  - Alonso-Menchén, David
AU  - Escolano-Fernández, Belén
AU  - Piniella-Ruiz, Esther
AU  - Alonso-Monge, Ester
AU  - Notario-Leo, Helena
AU  - Bibiano-Guillén, Carlos
AU  - Peña-Lillo, Gabriela
AU  - Antiqueira-Pérez, Armando
AU  - Romero-Pareja, Rodolfo
AU  - Cabello-Clotet, Noemí
AU  - Estrada-Pérez, Vicente
AU  - Troya-García, Jesús
AU  - de Carranza-López, María
AU  - Escobar-Rodríguez, Ismael
AU  - Vallejo-Maroto, Nacho
AU  - Torres-Macho, Juan
PY  - 2022
DO  - 10.1186/s13063-022-06722-x
UR  - http://hdl.handle.net/10668/20355
T2  - Trials
AB  - Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with...
LA  - en
KW  - Adult respiratory distress syndrome
KW  - COVID-19 pneumonia
KW  - Corticosteroids
KW  - Dexamethasone
KW  - Inflammatory biological markers
KW  - Laboratory markers
KW  - Mortality
KW  - Randomized controlled trial
KW  - Adrenal Cortex Hormones
KW  - Adult
KW  - C-Reactive Protein
KW  - COVID-19
KW  - Dexamethasone
KW  - Humans
KW  - Lactate Dehydrogenases
KW  - Multicenter Studies as Topic
KW  - Oxygen
KW  - Pneumonia
KW  - Randomized Controlled Trials as Topic
KW  - Respiratory Distress Syndrome
KW  - Respiratory Insufficiency
KW  - COVID-19 Drug Treatment
TI  - Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.
TY  - research article
VL  - 23
ER  -